Apparent relative hypermetabolism of selective brain areas in Huntington disease and importance of reference region for analysis

Clinical Nuclear Medicine

Volumn 37, Issue 7, 2012, Pages 663-668

  Lee, Su Jin ^a   Lee, Won Yong ^b   Kim, Yu Kyeong ^c   An, Young Sil ^a   Cho, Jin Whan ^b   Choi, Joon Young ^b   Kim, Byung Tae ^b   Lee, Kyung Han ^b  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

FDG PET; Huntington chorea; statistical parametric mapping

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN MAPPING; BRAIN METABOLISM; CAUDATE NUCLEUS; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPERMETABOLISM; IMAGE ANALYSIS; INFERIOR FRONTAL GYRUS; MALE; PONS; POSITRON EMISSION TOMOGRAPHY; STRIATE CORTEX; SUPERIOR FRONTAL GYRUS; THALAMUS; WHITE MATTER;

BRAIN; BRAIN MAPPING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS;

EID: 84862583296     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182478bf2     Document Type: Article

References (17)

1. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci. 2008;27:2803-2820.
2. Berent S, Giordani B, Lehtinen S, et al. Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23:541-546.
3. Kuwert T, Lange HW, Langen KJ, et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990;113:1405-1423.
4. Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol. 2009; 216:272-277.
5. Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol. 2007;9:223-233.
6. Browne SE. Mitochondria and Huntington's disease pathogenesis: Insight from genetic and chemical models. Ann N Y Acad Sci. 2008;1147:358-382.
7. Gu M, Gash MT, Mann VM, et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996;39:385-389.
8. Squitieri F, Cannella M, Frati L. Molecular medicine: Predicting and preventing Huntington's disease. Neurol Sci. 2008;29:205-207.
9. Rosenstock TR, Duarte AI, Rego AC. Mitochondrial-Associated metabolic changes and neurodegeneration in Huntington's diseaseVfrom clinical features to the bench. Curr Drug Targets. 2010;11:1218-1236.
10. Dukart J, Mueller K, Horstmann A, et al. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage. 2010;49:1490-1495.
11. Spence JS, Carmack PS, Gunst RF, et al. Using a white matter reference to remove the dependency of global signal on experimental conditions in SPECT analyses. Neuroimage. 2006;32:49-53.
12. Damiano M, Galvan L, Déglon N, et al. Mitochondria in Huntington's disease. Biochimica et Biophysica Acta. 2010;1802:52-61.
13. Brouillet E, Jacquard C, Bizat N, et al. 3-Nitropropionic acid: A mitochondria toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem. 2005;95:1521-1540.
14. Oláh J, Klivényi P, Gardián G, et al. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS J. 2008;275:4740-4755.
15. Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in earlyHuntington's disease: An [18F]FDGPET study.JNuclMed. 2001;42:1591-1595.
16. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain. 2007;130:2858-2867.
17. Hikosako O. Neural systems for control of voluntary actionVa hypothesis. Adv Biophys. 1998;35:81-102.